Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C8H15N7O2S3
CAS Number:
Molecular Weight:
337.45
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
famotidine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1
InChI
1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChI key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
Gene Information
human ... HRH2(3274)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Famotidine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
H2 histamine receptor antagonist; anti-ulcer agent
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
[Famotidine--a new histamine H2 receptor blockader].
P Ia Grigor'ev et al.
Klinicheskaia meditsina, 69(4), 23-28 (1991-04-01)
L P James et al.
Clinical pharmacokinetics, 31(2), 103-110 (1996-08-01)
Famotidine, an H2 receptor antagonist, has several potential advantages over cimetidine and ranitidine. These advantages include its potency, relatively longer elimination half-life, and lack of interaction with the cytochrome P450 isoforms. Eight studies addressing the use of famotidine in paediatric
Occupational allergic contact dermatitis from intermediate products in famotidine synthesis.
D Guimaraens et al.
Contact dermatitis, 31(4), 259-260 (1994-10-01)